Tag: AbTis
Beyond Random: Why Site-Specific Conjugation Is Redefining the ADC Therapeutic Window
Site-specific conjugation is reshaping how antibody-drug conjugates are engineered, replacing the structural heterogeneity of random conjugation with defined, homogeneous constructs. As multiple bioconjugation platforms...
WuXi XDC and AbTis to Advance Next-Generation ADCs
In a joint statement, WuXi XDC Cayman and AbTis announced a strategic partnership to advance the development and commercialization of a next-generations antibody-drug conjugates (ADC).
